WASHINGTON (dpa-AFX) - Novavax, Inc. (NVAX) has started a phase 2b clinical trial in South Africa to evaluate the efficacy of NVX-CoV2373, the company's COVID-19 vaccine candidate. In the Phase 1 portion of the Phase 1/2 clinical trial, conducted in Australia, NVX-CoV2373 was generally well-tolerated and showed robust antibody responses numerically superior to that seen in human convalescent sera.
NVX-CoV2373 is a prefusion protein made using the company's nanoparticle technology and includes Matrix-M adjuvant. The Coalition for Epidemic Preparedness Innovations (CEPI) is funding the manufacturing of doses of NVX-CoV2373 for the Phase 2b clinical trial.
Copyright RTT News/dpa-AFX
© 2020 AFX News
